Drug Profile
Levetiracetam controlled release - Sun Pharma Advanced Research Company
Alternative Names: Elepsia XR; Levetiracetam ER - Sun Pharma Advanced Research Company; Levetiracetam extended release - Sun Pharma Advanced Research CompanyLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Sun Pharma Advanced Research Company
- Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
- Mechanism of Action SV2A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Epilepsy
Most Recent Events
- 05 Nov 2019 China Medical System signed a licensing agreement with Sun Pharma Advanced Research for development and commercialisation of levetiracetam in China, Hong Kong, Macau and Taiwan
- 10 Jan 2018 Levetiracetam controlled release is still not refiled for regulatory approval for Epilepsy in USA (literature review)
- 30 Oct 2017 Levetiracetam controlled release is being considered for re-filing for regulatory approval in USA (PO) (SPARC pipeline, August 2017)